HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA reform

This article was originally published in The Rose Sheet

Executive Summary

FDA reform: House passes consolidated FDA reform/Prescription Drug User Fee reauthorization legislation (HR 1411) by voice vote Oct. 7 under suspension of rules. The measure, which cleared the Commerce Committee Sept. 25, retains FDA authority over cosmetics packaging and labeling and excludes any reference to establishing national uniformity for safety regs. The Administration favors amending the House bill to reflect Senate language, according to a policy statement issued Oct. 7. The White House wants to review device language and several other provisions in conference...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004731

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel